Literature DB >> 23569899

Evaluation of safety profile of black shilajit after 91 days repeated administration in rats.

C Velmurugan1, B Vivek, E Wilson, T Bharathi, T Sundaram.   

Abstract

OBJECTIVE: To evaluate the safety of shilajit by 91 days repeated administration in different dose levels in rats.
METHODS: In this study the albino rats were divided into four groups. Group I received vehicle and group II, III and IV received 500, 2 500 and 5 000 mg/kg of shilajit, respectively. Finally animals were sacrificed and subjected to histopathology and iron was estimated by flame atomic absorption spectroscopy and graphite furnace.
RESULTS: The result showed that there were no significant changes in iron level of treated groups when compared with control except liver (5 000 mg/kg) and histological slides of all organs revealed normal except negligible changes in liver and intestine with the highest dose of shilajit. The weight of all organs was normal when compared with control.
CONCLUSIONS: The result suggests that black shilajit, an Ayurvedic formulation, is safe for long term use as a dietary supplement for a number of disorders like iron deficiency anaemia.

Entities:  

Keywords:  Flame atomic absorption spectroscopy; Graphite furnace; Histopathology; Shilajit

Mesh:

Substances:

Year:  2012        PMID: 23569899      PMCID: PMC3609271          DOI: 10.1016/S2221-1691(12)60043-4

Source DB:  PubMed          Journal:  Asian Pac J Trop Biomed        ISSN: 2221-1691


  8 in total

Review 1.  Shilajit: a review.

Authors:  Suraj P Agarwal; Rajesh Khanna; Ritesh Karmarkar; Md Khalid Anwer; Roop K Khar
Journal:  Phytother Res       Date:  2007-05       Impact factor: 5.878

2.  Trypanosoma cruzi: treatment with the iron chelator desferrioxamine reduces parasitemia and mortality in experimentally infected mice.

Authors:  Jerusa Marilda Arantes; Maria Lúcia Pedrosa; Helen Rodrigues Martins; Vanja Maria Veloso; Marta de Lana; Maria Terezinha Bahia; Washington Luiz Tafuri; Cláudia Martins Carneiro
Journal:  Exp Parasitol       Date:  2007-03-24       Impact factor: 2.011

Review 3.  Complement activation pathways: a bridge between innate and adaptive immune responses in asthma.

Authors:  Marsha Wills-Karp
Journal:  Proc Am Thorac Soc       Date:  2007-07

Review 4.  Early iron deficiency has brain and behavior effects consistent with dopaminergic dysfunction.

Authors:  Betsy Lozoff
Journal:  J Nutr       Date:  2011-02-23       Impact factor: 4.798

Review 5.  A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis.

Authors:  M Mizuno
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

6.  Iron deficiency anemia and cognitive function in infancy.

Authors:  R Colin Carter; Joseph L Jacobson; Matthew J Burden; Rinat Armony-Sivan; Neil C Dodge; Mary Lu Angelilli; Betsy Lozoff; Sandra W Jacobson
Journal:  Pediatrics       Date:  2010-07-26       Impact factor: 7.124

7.  Antioxidant and hypolipidemic activity of Kumbhajatu in hypercholesterolemic rats.

Authors:  Rumi Ghosh; Parag P Kadam; Vilasrao J Kadam
Journal:  Int J Ayurveda Res       Date:  2010-07

8.  Relationship between gene expression of duodenal iron transporters and iron stores in hemochromatosis subjects.

Authors:  James E Nelson; Virginia R Mugford; Ellen Kilcourse; Richard S Wang; Kris V Kowdley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-05       Impact factor: 4.052

  8 in total
  3 in total

1.  The Human Skeletal Muscle Transcriptome in Response to Oral Shilajit Supplementation.

Authors:  Amitava Das; Soma Datta; Brian Rhea; Mithun Sinha; Muruganandam Veeraragavan; Gayle Gordillo; Sashwati Roy
Journal:  J Med Food       Date:  2016-07       Impact factor: 2.786

2.  Antiepileptic and antipsychotic activities of standardized Śilājatu (Shilajit) in experimental animals.

Authors:  Sharanbasappa Durg; Veeresh P Veerapur; B S Thippeswamy; Syed Mansoor Ahamed
Journal:  Anc Sci Life       Date:  2015 Oct-Dec

3.  Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment.

Authors:  T Kloskowski; K Szeliski; K Krzeszowiak; Z Fekner; Ł Kazimierski; A Jundziłł; T Drewa; M Pokrywczyńska
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.